Harrow has closed its previously announced acquisition of Tyrvaya (varenicline solution) nasal spray 0.03 mg from Viatris Inc. At closing, Harrow acquired worldwide rights to Tyrvaya, except for in Japan. Viatris retained the rights to commercialize Tyrvaya in Japan and agreed to pay Harrow royalties on any future net sales there. Consistent with the terms announced in August, Harrow paid $30 million in cash at closing and may pay up to $70 million in contingent milestone payments tied to Tyrvaya's net sales, for potential total consideration of up to $100 million. The closing payment was funded with cash on hand, the company said in a press release.
Tyrvaya is a cholinergic agonist indicated for the treatment of the signs and symptoms of dry eye disease. Tyrvaya is administered through the nose and is thought to activate the trigeminal parasympathetic pathway to stimulate basal tear production. Tyrvaya is approved in the United States, China, and Taiwan, with marketing applications pending in additional markets, the company said in the press release.
Tyrvaya will be available to eyecare professionals through Harrow's commercial organization immediately after closing. As part of the acquisition, Harrow said it expects approximately 40 employees from Viatris, with established knowledge of Tyrvaya and the dry eye market, to join and augment Harrow’s existing Ocular Surface commercial team. The company said it expects to onboard these new colleagues during the fourth quarter of 2026, and that its expanded Ocular Surface team will support both Vevye and Tyrvaya as the integration progresses.
According to the company, eyecare professionals can send Tyrvaya prescriptions using their electronic medical record software directly to Harrow’s dedicated pharmacy partner, PhilRx. Prescriptions can also be sent to any retail pharmacy. Tyrvaya is fully stocked in the wholesale distribution channel, including McKesson, Cardinal, and Cencora, and can be shipped to any retail pharmacy, generally within 24 hours of order placement, Harrow said. OM